Jinjia's New Tobacco Division Achieves Significant Revenue Growth

Apr.17.2023
Jinjia's New Tobacco Division Achieves Significant Revenue Growth
Jinjia Corp's 2022 report shows revenue growth in the new tobacco sector, aiming to build an e-cigarette manufacturing enterprise.

On April 15th, Jingjia Group released its 2022 Annual Board of Directors Work Report and 2022 Annual Financial Statement Report. The reports revealed that in 2022, the company achieved a revenue of 554 million yuan for its new tobacco products division, and a revenue of 1.949 billion yuan for its cigarette label products division.


According to a public announcement by Jingjia Corporation, the company's overall financial performance for 2022 is as follows:


The total operating revenue was 5.189 billion yuan, an increase of 2.41% year-on-year. Operating profit was 484 million yuan, a decrease of 59.54% year-on-year. The total profit was 332 million yuan, a decrease of 72.23% year-on-year.


In 2022, the financial results of the new tobacco industry are as follows:


Jinjia Corporation reported a revenue of 554 million yuan, representing a year-on-year increase of 227.72%. However, the company also saw a significant surge in operating costs, amounting to 515 million yuan, which marks a year-on-year increase of 254.46%. As a result, the company's gross profit margin declined by 7.01% year-on-year, settling at 7.04%. These figures were disclosed in Jinjia Corporation's annual report for 2022, which details the company's primary business outcomes.


JingJia Corporation reports product performance | Image source: JingJia Corporation 2022 annual report.


According to a report from Jingjia Incorporated, the company's main objectives in the new tobacco industry are to establish itself as a professional manufacturer of electronic cigarettes and to develop a brand of heating, non-burning "pod" products.


Jiangjiagong New Tobacco Business Structure


In terms of domestic operations, certain subsidiary companies within the new tobacco industry chain have obtained production licenses for tobacco monopolies. They are organizing production activities in accordance with approved production scope and quantity, with a primary focus on providing ODM/OEM services for new tobacco products such as electronic cigarettes, as well as research and development, production, and sales of vape oil, non-combustible heating fragrances and related supporting new materials.


In terms of overseas expansion, the company is establishing production bases for both vape and HNB industries, conducting research and development, manufacturing, and brand operations. It is also setting up a production base in Indonesia, with a focus on the research, manufacturing, and brand operations of tobacco heating products that do not burn tobacco, and the development of overseas channels.


Related reading:


Jingjia Corporation: Its subsidiary Shenzhen Yunpu Xinghe offers electronic cigarette export processing services for domestic and international clients.


JingJia Corporation announced that its electronic cigarette brand, Lono, has been sold to markets in Russia, the Philippines, and Malaysia.


Jincang Group's subsidiary companies, Wei Technology and Jinjia Technology, failed to obtain the necessary licenses from tobacco monopoly production enterprises.


Jinjia Corporation expects a 70-80% year-on-year decline in net profit to be around RMB 204-306 million in 2022.


Reference:


Jinjia Co., Ltd.: 2022 Annual Report of the Board of Directors' Work


Jinjia Co., Ltd. plans to release its annual financial report for the year 2022.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
The FDA has authorized four additional on! nicotine pouches, bringing the U.S. total to 30. The decision marks another outcome of the agency’s nicotine pouch review pilot, whose communication and review practices are now being applied more broadly across the category. It also extends Helix’s authorized portfolio from on! PLUS to the earlier on! line. Yet all FDA-authorized nicotine pouches still come from subsidiaries of PMI or Altria, underscoring how concentrated U.S. regulatory access remains.
Aug.05
Iowa Enforces Vape Registry Law as Retailers Warn Product Limits Could Increase Store Pressure
Iowa Enforces Vape Registry Law as Retailers Warn Product Limits Could Increase Store Pressure
Iowa has begun enforcing its vape registry law, requiring vape products to be registered before they can be legally sold in the state. The move follows a decision by the U.S. Court of Appeals for the Eighth Circuit to lift an injunction that had blocked enforcement. Retailers have warned that tighter product availability rules could increase pressure on vape shops. One Iowa retailer said that if only a limited number of products remain available, many stores could face significant business challenges.
Aug.06
IVG Parent Secures HMRC Excise Warehouse and Duty Stamp Approvals Ahead of UK Vape Tax
IVG Parent Secures HMRC Excise Warehouse and Duty Stamp Approvals Ahead of UK Vape Tax
Acme Vape Ltd, the company behind UK vaping brand IVG, has received HM Revenue & Customs approval to operate an excise warehouse for vaping products and participate in the Vaping Duty Stamps Scheme. The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Acme Vape Ltd says its approved warehouse in Preston will become operational under the new regime on the same date.
Regulations
Sep.18 by 2Firsts Perspectives
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives